Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

277 Press Releases
DateTitleCompany
19 Nov 13 Boehringer Ingelheim planning two new Global Clinical Trials for Pradaxa® (dabigatran etexilate) in expanded patient populations Boehringer Ingelheim,
Published by
Business Wire
19 Nov 13 New long-term treatment data confirms consistent benefit and safety profile of Pradaxa® beyond 6 years Boehringer Ingelheim,
Published by
Business Wire
18 Nov 13 First human data show promise of Boehringer Ingelheim’s specific antidote for immediate, complete and sustained reversal of Pradaxa®-induced anticoagulation Boehringer Ingelheim
18 Nov 13 First human data show promise of Boehringer Ingelheim’s specific antidote for immediate, complete and sustained reversal of Pradaxa®-induced anticoagulation Boehringer Ingelheim,
Published by
Business Wire
07 Nov 13 New data presented at AASD further demonstrate benefits of Trajenta® (linagliptin) with efficacy and safety in specific patient populations Boehringer Ingelheim,
Published by
Business Wire
28 Oct 13 New efficacy and safety data adds to evidence supporting treatment with afatinib* (GIOTRIF®) in Asian and non-Asian lung cancer patients Boehringer Ingelheim,
Published by
Business Wire
18 Oct 13 New once-daily Striverdi* (olodaterol) Respimat® gains approval in first EU countries Boehringer Ingelheim,
Published by
Business Wire
14 Oct 13 Boehringer Ingelheim submits nintedanib*, a novel oncology compound, for European approval Boehringer Ingelheim,
Published by
Business Wire
30 Sep 13 Nintedanib* extended survival beyond one year for advanced adenocarcinoma patients after prior first-line chemotherapy Boehringer Ingelheim,
Published by
Business Wire
27 Sep 13 New Irish online COPD resource at the click of a button Boehringer Ingelheim,
Published by
Porter Novelli
09 Sep 13 Landmark TIOSPIR™ trial further reinforces safety and efficacy profile of Spiriva® Respimat® in the treatment of COPD Boehringer Ingelheim
03 Sep 13 Pradaxa® (dabigatran etexilate) drives Boehringer Ingelheim’s innovation promise in cardiovascular diseases Boehringer Ingelheim,
Published by
Business Wire
17 Jul 13 Healthrageous, United BioSource and Boehringer Ingelheim launch SMART digital diabetes Study Boehringer Ingelheim, UBC,Healthrageous,
Published by
PharmiWeb.com
16 Jul 13 Benefits of Pradaxa® maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure Boehringer Ingelheim GmbH,
Published by
Business Wire
03 Jul 13 New research data supports safety benefits of Pradaxa in treatment of acute deep vein thrombosis and pulmonary embolism versus warfarin Boehringer Ingelheim
25 Jun 13 Trajenta® (linagliptin): New data on safety and efficacy in Type 2 Diabetes patients with moderate to severe renal impairment Boehringer Ingelheim and Eli Lilly and Company,
Published by
Ogilvy HealthPR London
25 Jun 13 New efficacy and safety data presented for Trajenta® (linagliptin) in Asians with Type 2 Diabetes Boehringer Ingelheim and Eli Lilly and Company,
Published by
Ogilvy HealthPR London
24 Jun 13 Application submitted to the EMA for use of dabigatran etexilate in treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE Boehringer Ingelheim
03 Jun 13 Superiority of afatinib* over comparator chemotherapy for patients with EGFR mutation-positive advanced lung cancer is reinforced by second Phase III study Boehringer Ingelheim,
Published by
Pharmiweb.com
21 May 13 Phase III results: Once-daily tiotropium* effective in symptomatic asthma patients irrespective of their age, allergic status, smoking status and bronchodilator response Boehringer Ingelheim
08 May 13 Boehringer Ingelheim joins Structural Genomics Consortium - for further research into uncurable diseases Boehringer Ingelheim
24 Apr 13 Boehringer Ingelheim consistently continues growth phase in financial year 2012 Boehringer Ingelheim
26 Mar 13 Boehringer Ingelheim and Eli Lilly and Company announce acceptance of European marketing authorisation application for investigational Type 2 Diabetes treatment empagliflozin* Boehringer Ingelheim,
Published by
Business Wire
26 Mar 13 FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate) Boehringer Ingelheim,
Published by
Business Wire
19 Mar 13 Boehringer Ingelheim and Lilly initiate MARLINA™ clinical trial to evaluate use of Trajenta® (linagliptin) in patients with type 2 diabetes and albuminuria Boehringer Ingelheim,
Published by
Business Wire
11 Mar 13 Pharmaco-invasive strategy including Metalyse® delivers comparable clinical outcomes to primary PCI for STEMI patients who could not undergo primary PCI within one hour from first medical contact Boehringer Ingelheim
11 Mar 13 American College of Cardiology and Boehringer Ingelheim collaborate to advance physician education with focus on China in 2013 Boehringer Ingelheim,
Published by
Business Wire
23 Feb 13 Phase III results: tiotropium* Respimat® is effective in symptomatic asthma patients irrespective of their allergic status Boehringer Ingelheim,
Published by
Business Wire
30 Jan 13 FDA Advisory Committee Recommends Approval for Boehringer Ingelheim’s Olodaterol* for Maintenance Treatment of COPD Boehringer Ingelheim
30 Jan 13 FDA Advisory Committee Recommends Approval for Boehringer Ingelheim’s Olodaterol* for Maintenance Treatment of COPD Boehringer Ingelheim,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.